Molecular genetic characteristics of gastric cancers from the surgeon’s point of view

V. G. Dubinina, A. A. Mashukov, O. V. Lukyanchuk, A. A. Bilenko, A. N. Zgura, D. V. Raciborsky, S. N. Lee

Abstract


Dubinina V. G., Mashukov A. A., Lukyanchuk O. V., Bilenko A. A., Zgura A. N., Raciborsky D. V., Lee S. N. Molecular genetic characteristics of gastric cancers from the surgeon’s point of view. Journal of Education, Health and Sport. 2016;6(11):592-621. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.200394

http://ojs.ukw.edu.pl/index.php/johs/article/view/4063

 

 

 

 

The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 755 (23.12.2015).

755 Journal of Education, Health and Sport eISSN 2391-8306 7

© The Author (s) 2016;

This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium,

provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License

(http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial

use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 02.11.2016. Revised 22.11.2016. Accepted: 30.11.2016.

 

MOLECULAR GENETIC CHARACTERISTICS OF GASTRIC CANCERS FROM THE SURGEON’S POINT OF VIEW

 

V. G. Dubinina1, A. A. Mashukov2, O. V. Lukyanchuk2, A. A. Bilenko1, A. N. Zgura2,

D. V. Raciborsky2, S. N. Lee2

 

1Odessa National Medical university

2Odessa Regional Oncology center

 

Summary

A study on the expression of oncoproteins in stomach` carcinomas, has been turned into a real research basically due to the abundance of results and their comprehensive interpretations. The study carried out on the abdominal onco-surgical department ofOdessaRegionalOncologyCenter, included a study of 188 patients operated on for gastric cancer (GC) between 2007-2011. Inall cases was performed the so-called lymphadenectomy for the principal reason of extensive preventive biopsy of visually unchanged lymph nodes. We spend a multivariate analysis of interactions between the expression of oncoproteins  p53, VEGFR-3, erbB2, Ki67 and micro involvement of tumor vasculature (ly, v), the local growth (T), the presence of residual tumor tissue (the R), the degree of tumor differentiation (the G) the degree of regional lymph nodes involvement (N) and type of infiltration (Inf α, β, Inf Υ).

Keywords: Stomach cancer, Immunohistochemistry and Oncoproteins.

Keywords


Stomach cancer, Immunohistochemistry and Oncoproteins

Full Text:

PDF

References


Gerstein ES, Lee SN, AB Ryabov et al. (2009) Comparative study immunosorbent matrix metalloproteinase-2, -7, -9 and tissue inhibitor type 2 in tumors and blood plasma of patients with gastric cancer. Bull. exp. biol. Med., 148 (12):. 660-663.

McGee S. (2002) Simplifying Likelihood Ratios. J Gen Intern Med.,17(8): 647–650.

Liao X., Lochhead P., Nishihara R. et al. (2012) Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. N Engl J Med, 367: 1596-1606.

Ayral-Kaloustian S., Salaski E.J. (2002) Protein farnesyltransferase inhibitors. Curr Med Chem., 9(10): 1003-1032.

Amato M., Perrone G., Righi D. et al. (2016) HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. Pathol Oncol Res., 30: 1-7.

Huang G., Chen S., Wang D., Wang R., Lin L., Chen S., Wang L., Huang Q. (2016) High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma. Clin Lab. 62(1-2):141-53.

Kanayama K., Imai H., Yoneda M., Hirokawa Y.S., Shiraishi T. (2016) Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci. Apr;107(4):536-42. doi: 10.1111/cas.12886. Epub 2016 Feb 19.

De Silva N., Schulz L., Paterson A., Qain W., Secrier M., Godfrey E., Cheow H., O'Donovan M., Lao-Sirieix P., Jobanputra M., Hochhauser D., Fitzgerald R., Ford H. (2015) Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. Br J Cancer. Nov 3;113(9):1305-12. doi: 10.1038/bjc.2015.342. Epub 2015 Oct 20. PMID:26484410.

Chen T., Xu X.Y., Zhou P.H.. (2016) Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer. May 27;35(1):49. doi: 10.1186/s40880-016-0111-5. Review. PMID:27233623.

Nadauld L.D., Ford J.M.. (2013) Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol. 31(7):838–839. doi: 10.1200/JCO.2012.47.1714.

Stahl P., Seeschaaf C., Lebok P., Kutup A., Bockhorn M., Izbicki J.R., et al. (2015) Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 15:7.

Zhang W. (2014) TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chin J Cancer. 33(10):469–470.

Murphy G., Pfeiffer R., Camargo M.C., Rabkin C.S. (2009) Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 137(3):824–833.

Burke A.P., Yen T.S., Shekitka K.M., Sobin L.H. (1990) Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol. 3(3):377–380.

Kaneda A., Matsusaka K., Aburatani H., Fukayama M. (2012) Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 72(14):3445–3450. doi: 10.1158/0008-5472.CAN-11-3919.

Chen T., Sun Y., Ji P., Kopetz S., Zhang W. (2015) Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. 34(31):4019–4031. doi: 10.1038/onc.2014.332.

Cidon E.U., Ellis S.G., Inam Y., Adeleke S., Zarif S., Geldart T. (2013) Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) 5(1):64–91. doi: 10.3390/cancers5010064.

Jong Gwang Kim. (2013) Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med. 28(2): 149–155. PMCID: PMC3604602.

Penault-Llorca F., André F., Sagan C., Lacroix-Triki M., Denoux Y., Verriele V., Jacquemier J., Baranzelli M.C., Bibeau F., Antoine M., Lagarde N., Martin A.L., Asselain B., Roché H. (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 27(17):2809-15. doi: 10.1200/JCO.2008.18.2808. Epub 2009 Apr 20.

Tsai H.L., Lin C.H., Huang C.W., Yang I.P., Yeh Y.S., Hsu W.H., Wu J.Y., Kuo C.H., Tseng F.Y., Wang J.Y. (2015) Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol. 1;8(2):1900-10.

Weiguo Cao, Rong Fan, Weiping Yang, Yunlin Wu. (2014) VEGF-C expression is associated with the poor survival in gastric cancer tissue. Tumor Biology. Volume 35, Issue 4, pp 3377-3383.

Hong-Feng Gou, Xin-Chuan Chen, Jiang Zhu, Ming Jiang, Yu Yang, Dan Cao, and Mei Hou. (2011) Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011; 30(1): 14. PMCID: PMC3037339 (полнотекстовая).

Makoto Ishikawa, Joji Kitayama, Shinsuke Kazama and Hirokazu Nagawa (2016). Expression of Vascular Endothelial Growth Factor C and D (VEGF-C and -D) is an Important Risk Factor for Lymphatic Metastasis in Undifferentiated Early Gastric Carcinoma. Japanese Journal of Clinical Oncology. Volume 33, Issue 1. Pp. 21-27 (полнотекстовая).

Yutaka Yonemura , Yoshio Endo, Kayoko Tabata, Taiichi Kawamura, Hyo-Yung Yun, Etsurou Bandou, Takuma Sasaki, Masahiro Miura (2005). Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. International Journal of Clinical Oncology. Volume 10, Issue 5, pp 318-327.

Angela Moliterni, Sylvie Ménard, Pinuccia Valagussa, Elia Biganzoli, Patrizia Boracchi, Andrea Balsari, Patrizia Casalini, Gorana Tomasic, Ettore Marubini, Silvana Pilotti and Gianni Bonadonna (2003). HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer. doi: 10.1200/JCO.2003.04.021. JCO vol. 21 no. 3 458-462 (полнотекстовая - http://jco.ascopubs.org/content/21/3/458.full).

Ananiev J., Gulubova M., Manolova I., Tchernev G. (2011). Prognostic significance of HER2/neu expression in gastric cancer. Article (PDF Available) in Wiener klinische Wochenschrift 123(13-14):450-4.

Jørgensen J. T., Hersom M. (2012) HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer 3:137-144. doi:10.7150/jca.4090 (полнотекстовая).

Gravalos C.; Jimeno A. (2008) HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Ann Oncol. 19(9):1523-1529 (полнотекстовая).

Rüschoff J., et al. (2012) HER2 testing in gastric cancer: a practical approach. Modern Pathology 25, 637–650.

Sheffield B.S., Garratt J., Kalloger S.E., Li-Chang H.H., Torlakovic E.E., Gilks C.B., Schaeffer D.F. (2014) HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. Arch Pathol Lab Med. 138(11):1495-502. doi: 10.5858/arpa.2013-0604-OA.

Japanese Classification of Gastric Carcinoma – 2nd English Edition – Japanese Gastric Cancer Association. Gastric Cancer (1998) 1: 10-24

Zhang Y.Y., Gu K.S., Wu H.Y., Yang F., Bu L.J., Zhao C.C., Zhang Y.R. (2015) Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Genet Mol Res. 14(4):15921-9. (полнотекстовая).

Munroe M., Kolesar J. (2016) Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Am J Health Syst Pharm. 15;73(14):1037-41.

Moiseyenko V.M., Chubenko V.A., Moiseyenko F.V., Zhabina A.S., Gorodnova T.V., Komarov Y.I., Bogdanov A.A., Sokolenko A.P., Imyanitov E.N. (2014) Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol. 31(10):199. doi: 10.1007/s12032-014-0199-x. Epub 2014 Sep 4.

Kriege M., Jager A., Hooning M.J., Huijskens E., Blom J., van Deurzen C.H., Bontenbal M., Collee J.M., Menke-Pluijmers M.B., Martens J.W., Seynaeve C. (2012) The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. 118(4):899-907.

Alessandro Lugli, Inti Zlobec, Gad Singer, Andrea Kopp Lugli, Luigi M Terracciano and Robert M Genta*. (2007) Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nature Clinical Practice Gastroenterology & Hepatology 4, 52-57.

James P.A., Mitchell G., Bogwitz M., Lindeman G.J. (2013) The Angelina Jolie effect. Med J Aust. 18;199(10):646.

Kawata S., Yashima K., Yamamoto S., Sasaki S., Takeda Y., Hayashi A., Matsumoto K., Kawaguchi K., Harada K., Murawaki Y. (2015) AID (activation-induced cytidine deaminase), p53 and MLH1 expression in early gastric neoplasms and the correlation with the background mucosa. Oncol Lett. 10(2):737-743.

Li Z., Lai Y., Sun L., Zhang X., Liu R., Feng G., Zhou L., Jia L., Huang X., Kang Q., Lin D., Gao J., Shen L. (2016) PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol. 31. pii: S0046-8177(16)30093-4.

Nanda R., Chow L.Q., Dees E.C., Berger R., Gupta S., Geva R., Pusztai L., Pathiraja K., Aktan G., Cheng J.D., Karantza V., Buisseret L. (2016) Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2. pii: JCO648931. [Epub ahead of print]

Muro K., Chung H.C., Shankaran V., Geva R., Catenacci D., Gupta S., Eder J.P., Golan T., Le D.T., Burtness B., McRee A.J., Lin C.C., Pathiraja K., Lunceford J., Emancipator K., Juco J., Koshiji M., Bang Y.J. (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17(6):717-26.

Shigeyasu K., Nagasaka T., Mori Y., Yokomichi N., Kawai T., Fuji T., Kimura K., Umeda Y., Kagawa S., Goel A., Fujiwara T. (2015) Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer. PLoS One. 10(6):e0130409.

He D., Zhang Y.W., Zhang N.N., Zhou L., Chen J.N., Jiang Y., Shao C.K. (2015) Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas. Med Oncol. 32(4):92.

YING HUANG, PUYUAN W.U., BAORUI LI.U, and JUAN D.U. (2016) Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report. Oncol Lett. 11(6): 4183–4186. PMCID: PMC4888084.

Qiao G.L., Qi W.X., Jiang W.H., Chen Y., Ma L.J. (2016) Prognostic significance of circulating tumor cells in esophageal carcinoma: a meta-analysis. Onco Targets Ther. 9:1889-97.

Tsai W.S., Chen J.S., Shao H.J., Wu J.C., Lai J.M., Lu S.H., Hung T.F., Chiu Y.C., You J.F., Hsieh P.S., Yeh C.Y., Hung H.Y., Chiang S.F., Lin G.P., Tang R., Chang Y.C. (2016) Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. Sci Rep. 6:24517.

Gao Z.H., Wang Q.Q. (2015) Curative effect of paclitaxel and cisplatin combined chemotherapy on cervical cancer and its relation with tissue micro vascular and lymphatic vessels density. Pak J Pharm Sci. 28(5 Suppl):1849-52.

Guastadisegni C., Colafranceschi M., Ottini L., Dogliotti E. (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta analysis of colorectal cancer survival data // Europ. J. Cancer. Vol.46. – P.2788-2798.

Vilar E., Gruber S.B. (2010) Microsatellite instability in colorectal cancer - the stable evidence // Nat. Rev. Clin. Oncol. Vol.7. – P.153-162.

Imyanitov E.N., Moiseyenko V.M. (2011) Drug therapy for hereditary cancers. Hered Cancer Clin Pract. 9(1):5.

Boland C.R., Goel A. (2010) Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–2087. doi: 10.1053/j.gastro.2009.12.064. [PMC free article]

Vilar E., Gruber S.B. (2010) Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 7:153–162.

Clark A.J., Barnetson R., Farrington S.M., Dunlop M.G. (2004) Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer. 2004;3:85–91.

Popat S., Hubner R., Houlston R.S. (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 23:609–618.

Guastadisegni C., Colafranceschi M., Ottini L., Dogliotti E. (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer. 46:2788–2798. doi: 10.1016/j.ejca.2010.05.009. [PubMed] [Cross Ref]

Hewish M., Lord C.J., Martin S.A., Cunningham D., Ashworth A. (2010) Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 7:197–208. doi: 10.1038/nrclinonc.2010.18. [PubMed] [Cross Ref]

Laghi L., Bianchi P., Malesci A. (2008) Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene. 27:6313–6321. doi: 10.1038/onc.2008.217. [PubMed] [Cross Ref]

Perucho M. (1999) Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248-5257. Cancer Res. 1999;59:249–256. [PubMed]

Vilar E., Scaltriti M., Balmaña J., Saura C., Guzman M., Arribas J., Baselga J., Tabernero J. (2008) Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer. 99:1607–1612.

Martin S.A., McCarthy A., Barber L.J., Burgess D.J., Parry S., Lord C.J., Ashworth A. (2009) Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med. 1:323–337. doi: 10.1002/emmm.200900040.

Valentini A.M., Armentano R., Pirrelli M., Caruso M.L. (2006) Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer Treat Rev. 32:607–618. doi: 10.1016/j.ctrv.2006.08.001.

Papouli E., Cejka P., Jiricny J. (2004) Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 64:3391–3394. doi: 10.1158/0008-5472.CAN-04-0513.

Yamane K., Schupp J.E., Kinsella T.J. (2007) BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage. Cancer Res. 67:6286–6292. doi: 10.1158/0008-5472.CAN-06-2205.

Fink D., Zheng H., Nebel S., Norris P.S., Aebi S., Lin T.P., Nehmé A., Christen R.D., Haas M., MacLeod C.L., Howell S.B. (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57:1841–1845.

Martin S.A., Hewish M., Sims D., Lord C.J., Ashworth A. (2011) Parallel high throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair deficient cancers. Cancer Res. 71:1836–1848. doi: 10.1158/0008-5472.CAN-10-2836.

Martin S.A., McCabe N., Mullarkey M., Cummins R., Burgess D.J., Nakabeppu Y., Oka S., Kay E., Lord C.J., Ashworth A. (2010) DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 17:235–248. doi: 10.1016/j.ccr.2009.12.046.

des Guetz G., Schischmanoff O., Nicolas P., Perret G.Y., Morere J.F, Uzzan B. (2009) Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 45:1890–1896.

Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., Tu D., Redston M., Gallinger S. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. doi: 10.1056/NEJMoa022289.

Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., French A.J., Kabat B., Foster N.R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz J.F., Sinicrope F., Gallinger S. (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 28:3219–3226. doi: 10.1200/JCO.2009.27.1825.

de Vos tot Nederveen Cappel W.H., Meulenbeld H.J., Kleibeuker J.H., Nagengast F.M., Menko F.H., Griffioen G., Cats A., Morreau H., Gelderblom H., Vasen H.F. (2004) Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer. 109:468–471. doi: 10.1002/ijc.11712.

Sinicrope F.A., Sargent D.J. (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol. 21:369–373. doi: 10.1097/CCO.0b013e32832c94bd.

de la Chapelle A., Hampel H. (2010) Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 28:3380–3387. doi: 10.1200/JCO.2009.27.0652.

Kim S.T., Lee J., Park S.H., Park J.O., Lim H.Y., Kang W.K., Kim J.Y., Kim Y.H., Chang D.K., Rhee P.L., Kim D.S., Yun H., Cho Y.B., Kim H.C., Yun S.H., Lee W.Y., Chun H.K., Park Y.S. (2010) Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol. 66:659–667.

Zaanan A., Cuilliere-Dartigues P., Guilloux A., Parc Y., Louvet C., de Gramont A., Tiret E., Dumont S., Gayet B., Validire P., Fléjou JF., Duval A., Praz F. (2010) Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 21:772–780.

Bertagnolli M.M., Niedzwiecki D., Compton C.C., Hahn H.P., Hall M., Damas B., Jewell S.D., Mayer R.J., Goldberg R.M., Saltz L.B., Warren R.S., Redston M. (2009) Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 27:1814–1821. doi: 10.1200/JCO.2008.18.2071.

Liang J.T., Huang K.C., Lai H.S., Lee P.H., Cheng Y.M., Hsu H.C., Cheng A.L., Hsu C.H., Yeh K.H., Wang S.M., Tang C., Chang K.J. (2002) High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer. 101:519–525.

Brueckl W.M., Moesch C., Brabletz T., Koebnick C., Riedel C., Jung A., Merkel S., Schaber S., Boxberger F., Kirchner T., Hohenberger W., Hahn E.G., Wein A. (2003) Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res. 23:1773–1777.

des Guetz G., Mariani P., Cucherousset J., Benamoun M., Lagorce C., Sastre X., Le Toumelin P., Uzzan B., Perret G.Y., Morere J.F., Breau J.L., Fagard R., Schischmanoff P.O. (2007) Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 27:2715–2719.

Müller C.I., Schulmann K., Reinacher-Schick A., Andre N., Arnold D., Tannapfel A., Arkenau H., Hahn S.A., Schmoll S.H., Porschen R., Schmiegel W., Graeven U. (2008) AIO Colorectal Study Group. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 23:1033–1039.

Kim S.T., Lee J., Park S.H., Park J.O., Lim H.Y., Kang W.K., Kim J.Y., Kim Y.H., Chang D.K., Rhee P.L., Kim D.S., Yun H., Cho Y.B., Kim H.C., Yun S.H., Chun H.K., Lee W.Y., Park Y.S. (2010) The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol. 27:1277–1285. doi: 10.1007/s12032-009-9374-x.

Fallik D., Borrini F., Boige V., Viguier J., Jacob S., Miquel C., Sabourin J.C., Ducreux M., Praz F. (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 63:5738–5744.

Charara M., Edmonston T.B., Burkholder S., Walters R., Anne P., Mitchell E., Fry R., Boman B., Rose D., Fishel R., Curran W., Palazzo J. (2004) Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res.;24:3161–3167.

Bendardaf R., Lamlum H., Ristamäki R., Korkeila E., Syrjänen K., Pyrhönen S. (2007) Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. Tumour Biol. 28:212–220. doi: 10.1159/000107417.

Kim J.E., Hong Y.S., Ryu M.H., Lee J.L., Chang H.M., Lim S.B., Kim J.H., Jang S.J., Kim M.J., Yu C.S., Kang Y.K., Kim J.C., Kim T.W. (2011) Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci. in press.




DOI: http://dx.doi.org/10.5281/zenodo.200394

Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 © The Author (s) 2016

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

Journal Language(s): English 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2  www.ukw.edu.pl Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy http://ojs.ukw.edu.pl/index.php/johs  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase Index.com.

Website: www.infobaseindex.com

Universal Impact Factor 1.78 for year 2012. (http://www.uifactor.org/AppliedJournals.aspx)

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)